Extract
We read with great interest the recent publication by Kwak et al. [1] involving a meta-analysis of studies reporting treatment outcomes for Mycobacterium abscessus pulmonary disease (MAB-PD). The authors should be commended for identifying the association between azithromycin, amikacin and imipenem, and improved clinical outcome in MAB-PD.
Abstract
A combination of pharmacokinetics and pharmacodynamics is required to evaluate the efficacy of antimicrobial drugs in the treatment of Mycobacterium abscessus http://bit.ly/2OGwS3C
Footnotes
Conflict of interest: H.Y. Kim has nothing to disclose.
Conflict of interest: V. Sintchenko has nothing to disclose.
Conflict of interest: J-W. Alffenaar has nothing to disclose.
- Received July 30, 2019.
- Accepted August 1, 2019.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
